FARMINGDALE, N.Y.--(BUSINESS WIRE)--Misonix, Inc. (NASDAQ: MSON), a developer of ultrasonic medical device technology for the treatment of cancer and other chronic health conditions, today announced that it has further expanded its European business of High Intensity Focused Ultrasound (“HIFU”) using the Sonablate® 500 (“SB500”) for prostate cancer treatment through a distribution agreement with Partnermed AS for the SB500 in the Northern European countries of Norway and Sweden. With the entry into these two new countries, Misonix has further extended its lead as the most widely available HIFU prostate cancer treatment in Europe.
